Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | S100A4 | P26447 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010961 | 0.84 | TDP1 (0.61) | TDP1SMN1; SMN2GPR35TSHRALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28763100 | 0.82 | TDP1 (0.58) | TDP1SMN1; SMN2GPR35TSHRALDH1A1 | |
| SCHEMBL26164138 | 0.82 | PDE7A (0.46) | TDP1SMN1; SMN2PDE7AGPR35ALDH1A1 | |
| SCHEMBL29565972 | 0.82 | PDE7A (0.46) | TDP1SMN1; SMN2PDE7AGPR35ALDH1A1 | |
| SCHEMBL4063467 | 0.81 | ALDH1A1 (0.50) | TDP1SMN1; SMN2PDE7AGPR35TSHR | |
| Valine SCHEMBL10510465 | 0.81 | SLC7A5 (0.41) | TDP1SMN1; SMN2PDE7AGPR35TSHR | |
| SCHEMBL31713028 | 0.79 | S100A4 (0.45) | TDP1SMN1; SMN2PDE7AGPR35ALDH1A1 | |
| SCHEMBL29655222 | 0.79 | S100A4 (0.45) | TDP1SMN1; SMN2PDE7AGPR35ALDH1A1 | |
| SCHEMBL24548 | 0.78 | TDP1 (0.60) | TDP1SMN1; SMN2PDE7AGPR35TSHR | |
| SCHEMBL307855 | 0.78 | TDP1 (0.54) | TDP1SMN1; SMN2GPR35TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025043967-A1 | PREPARATION METHOD FOR AND USE OF NANOPOROUS CARBON MATERIAL HAVING CONTINUOUS STRUCTURE | 东南大学 | 2025-03-06 | — | — | WO | claimed |
| CN-118515261-A | Preparation method of nano porous carbon material with continuous structure and application of nano porous carbon material as heat insulation material | 东南大学 | 2024-08-20 | — | — | CN | claimed |
| CN-117088357-A | Preparation method and application of nano porous carbon material with continuous structure | 东南大学 | 2023-11-21 | — | — | CN | claimed |
| US-7539006-B2 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2009-05-26 | — | — | US | claimed |
| US-20070029529-A1 | Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor | KOMATSU AKIHIKO | 2007-02-08 | — | — | US | claimed |
| US-20040245105-A1 | Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| EP-1437749-A1 | ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR | Rubycon Corporation (JP) | 2004-07-14 | — | — | EP | claimed |
| US-RE30798-E | BY REACTING 4-FLUORO-3-NITROANILINES WITH AMMONIA OR A PRIMARY OR SECONDARY AMINE | CLAIROL INCORPORATED (US) | 1981-11-17 | — | — | US | claimed |
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250177484-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | NAMMI THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12311010-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025096706-A1 | MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025043967-A1 | PREPARATION METHOD FOR AND USE OF NANOPOROUS CARBON MATERIAL HAVING CONTINUOUS STRUCTURE | 东南大学 | 2025-03-06 | — | — | WO | disclosed |
| US-5587392-A | THERAPY FOR ESTROGEN DEPENDENT DISEASES | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| EP-0684235-A1 | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-29 | — | — | EP | disclosed |
| US-4857070-A | 2,4-Diaminophenyl tetrahydrofurfuryl ethers, processes for their preparation and tinting compositions, which contain them for keratinic fibres | SEIDEL WINFRIED (DE) | 1989-08-15 | — | — | US | disclosed |
| EP-0000121-A1 | 6-(1-Piperazinyl)-quinoxaline, process for its preparation and pharmaceutical compositions thereof | MERCK & CO. INC. (US) | 1979-01-10 | — | — | EP | disclosed |
| US-4091101-A | ANORECTIC AGENTS | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-3959377-A | FROM 4-FLUORO-3-NITROANILINE AND ANILINE | CLAIROL INCORPORATED (US) | 1976-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243188-A1 | METHIONINE ADENOSYLTRANSERASE 2A INHIBITORS | MAT2A, MAT2B, MAT1A | TDP1 809/4885SMN1; SMN2 1209/4885PDE7A 852/4885 |
| US-12311010-B2 | Formulated and/or co-formulated liposome compositions containing toll-like receptor(“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof | TLR1, TLR4, TLR7 | TDP1 1458/4885SMN1; SMN2 2645/4885PDE7A 765/4885 |
| US-20250177484-A1 | Formulated and/or Co-Formulated Liposome Compositions Containing Toll-Like Receptor (TLR) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | TLR1, TLR7, TLR4 | TDP1 1004/4885SMN1; SMN2 2536/4885PDE7A 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.